Kadcyla (ado-trastuzumab emtansine, or T-DM1) has a terminal elimination half-life of about 4 days. That means it takes roughly 20 days for the intact drug to be essentially cleared from your bloodstream, since most drugs are considered eliminated after about five half-lives. However, some of its components and side effects can linger beyond that window, which is why surgical washout recommendations call for a full 4-week gap from your last dose.
Half-Life and Clearance Timeline
Kadcyla is an antibody-drug conjugate, meaning it’s a large antibody molecule (trastuzumab) chemically linked to a potent chemotherapy payload (DM1). The intact conjugate clears from the body at a rate of about 0.68 liters per day, giving it a median half-life between 3.9 and 4.5 days depending on the study. After each half-life, roughly half of the remaining drug is gone. By day 20 to 23 after your last infusion, the intact conjugate has dropped to negligible levels.
Kadcyla does not accumulate significantly between doses. Because the drug is given every 3 weeks and the half-life is only about 4 days, steady state is reached during the very first cycle. Each new infusion essentially starts fresh rather than stacking on top of leftover drug from the previous dose.
How the Body Breaks Down Kadcyla
Once Kadcyla binds to HER2-positive cancer cells, it gets pulled inside the cell and broken apart in compartments called lysosomes. This releases the DM1 payload, which does the cell-killing work. The DM1 that escapes cells is rapidly cleared, partly through the liver and biliary system. None of the drug appears to be eliminated through the kidneys.
The linker connecting the antibody to DM1 can also break apart on its own through a chemical reaction, releasing small amounts of free DM1 or DM1 attached to a blood protein called albumin. These byproducts are cleared quickly relative to the intact conjugate, so the 4-day half-life of the whole molecule is the number that matters most for estimating how long it stays in your system.
How Long Side Effects Last
Even after the drug itself clears, its effects on your body take additional time to resolve. The most common example is low platelet counts. Nearly all patients on Kadcyla experience a temporary drop in platelets, with the lowest point typically hitting about 8 days after an infusion. Platelet counts then recover by around day 15 of the cycle, well before the next dose is due. If your platelet count drops significantly, your oncologist may delay the next infusion until levels bounce back.
Liver enzyme elevations are another common side effect. Like platelet changes, these tend to improve between cycles and don’t necessarily worsen with continued treatment. But because the liver is the primary organ responsible for eliminating the DM1 component, liver-related effects deserve close monitoring throughout treatment.
Recommended Washout Periods
If you’re having surgery, current recommendations call for stopping Kadcyla at least 4 weeks before the procedure and waiting 3 to 4 weeks after surgery before restarting. This buffer accounts not just for drug clearance but also for the platelet and liver effects that could increase bleeding risk or complicate healing.
For pregnancy planning, the same principle applies: the drug itself may be gone in about 3 weeks, but a longer washout gives your body time to fully normalize. Your oncologist can help determine the right timeline based on your specific situation.
Factors That Affect Clearance Speed
Kidney function has little impact on how fast Kadcyla leaves your system. Studies of patients with mild to moderate kidney impairment show no meaningful change in drug levels compared to patients with normal kidney function. This makes sense given that the drug is not eliminated through the kidneys.
Liver function is more relevant since the liver processes the DM1 component. Interestingly, patients with mild or moderate liver impairment actually showed lower initial drug exposure during the first cycle, but by the third cycle their levels were within the normal range. No dose adjustment is needed for mild or moderate liver impairment, though closer monitoring is standard. Kadcyla has not been studied in patients with severe liver impairment.
Body weight affects the total amount of drug you receive because dosing is based on weight (3.6 mg per kilogram), but the rate of clearance per unit of body size remains relatively consistent across patients. Age, race, and mild organ impairment have not been shown to meaningfully change how long the drug stays in your system.